DK1112066T3 - Anvendelse af methoxymorpholino doxorubicin til behandlingen af en levertumor - Google Patents

Anvendelse af methoxymorpholino doxorubicin til behandlingen af en levertumor

Info

Publication number
DK1112066T3
DK1112066T3 DK99944533T DK99944533T DK1112066T3 DK 1112066 T3 DK1112066 T3 DK 1112066T3 DK 99944533 T DK99944533 T DK 99944533T DK 99944533 T DK99944533 T DK 99944533T DK 1112066 T3 DK1112066 T3 DK 1112066T3
Authority
DK
Denmark
Prior art keywords
treatment
liver tumor
methoxymorpholino doxorubicin
methoxymorpholino
doxorubicin
Prior art date
Application number
DK99944533T
Other languages
Danish (da)
English (en)
Inventor
Maria Adele Pacciarini
Olga Valota
David Kerr
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Application granted granted Critical
Publication of DK1112066T3 publication Critical patent/DK1112066T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK99944533T 1998-09-14 1999-08-27 Anvendelse af methoxymorpholino doxorubicin til behandlingen af en levertumor DK1112066T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9820012.4A GB9820012D0 (en) 1998-09-14 1998-09-14 Use of an anthracycline derivative for the treatment of a liver tumor
PCT/EP1999/006298 WO2000015203A2 (en) 1998-09-14 1999-08-27 Use of methoxymorpholino doxorubicin for the treatment of a liver tumor

Publications (1)

Publication Number Publication Date
DK1112066T3 true DK1112066T3 (da) 2003-11-03

Family

ID=10838847

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99944533T DK1112066T3 (da) 1998-09-14 1999-08-27 Anvendelse af methoxymorpholino doxorubicin til behandlingen af en levertumor

Country Status (26)

Country Link
EP (1) EP1112066B1 (zh)
JP (2) JP5529360B2 (zh)
KR (1) KR100685155B1 (zh)
CN (1) CN1168452C (zh)
AT (1) ATE245029T1 (zh)
AU (1) AU773451B2 (zh)
BR (1) BR9913627A (zh)
CA (1) CA2343120C (zh)
CZ (1) CZ295901B6 (zh)
DE (1) DE69909636T2 (zh)
DK (1) DK1112066T3 (zh)
EA (1) EA004570B1 (zh)
ES (1) ES2203175T3 (zh)
GB (1) GB9820012D0 (zh)
HK (1) HK1050853A1 (zh)
HU (1) HU229186B1 (zh)
ID (1) ID28035A (zh)
IL (2) IL141645A0 (zh)
MY (1) MY124247A (zh)
NO (1) NO329746B1 (zh)
NZ (1) NZ510445A (zh)
PL (1) PL198025B1 (zh)
PT (1) PT1112066E (zh)
TW (1) TWI222868B (zh)
UA (1) UA69423C2 (zh)
WO (1) WO2000015203A2 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9909925D0 (en) * 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
WO2004038404A2 (en) * 2002-10-28 2004-05-06 Pharmacia Italia Spa Method for optimizing therapeutic efficacy of nemorubicin
US20060264388A1 (en) * 2003-02-26 2006-11-23 Olga Valota Method for treating liver cancer by intrahepatic administration of nemorubicin
US8940334B2 (en) 2007-05-11 2015-01-27 Nerviano Medical Sciences S.R.L. Pharmaceutical composition of an anthracycline
JP2016124818A (ja) * 2014-12-26 2016-07-11 日本化薬株式会社 転移性肝癌治療薬及び転移性肝癌の治療方法
PL244818B1 (pl) * 2021-11-03 2024-03-11 Urteste Spolka Z Ograniczona Odpowiedzialnoscia Związek-marker diagnostyczny raka wątroby, sposób wykrywania aktywności enzymatycznej, sposób diagnozowania raka wątroby, zestaw zawierający taki związek oraz związek do zastosowania medycznego

Also Published As

Publication number Publication date
EA200100353A1 (ru) 2001-10-22
GB9820012D0 (en) 1998-11-04
MY124247A (en) 2006-06-30
EP1112066A2 (en) 2001-07-04
WO2000015203A3 (en) 2000-07-20
TWI222868B (en) 2004-11-01
NO329746B1 (no) 2010-12-13
DE69909636T2 (de) 2004-06-09
NO20011116D0 (no) 2001-03-05
HUP0103557A2 (hu) 2002-01-28
KR100685155B1 (ko) 2007-02-22
NZ510445A (en) 2003-01-31
PL198025B1 (pl) 2008-05-30
KR20010075074A (ko) 2001-08-09
DE69909636D1 (de) 2003-08-21
IL141645A0 (en) 2002-03-10
CN1168452C (zh) 2004-09-29
NO20011116L (no) 2001-05-14
AU773451B2 (en) 2004-05-27
PT1112066E (pt) 2003-11-28
CA2343120C (en) 2009-11-24
ATE245029T1 (de) 2003-08-15
UA69423C2 (uk) 2004-09-15
CZ295901B6 (cs) 2005-11-16
IL141645A (en) 2007-05-15
CA2343120A1 (en) 2000-03-23
JP2002524496A (ja) 2002-08-06
ES2203175T3 (es) 2004-04-01
JP2014088398A (ja) 2014-05-15
EP1112066B1 (en) 2003-07-16
BR9913627A (pt) 2001-05-22
WO2000015203A2 (en) 2000-03-23
EA004570B1 (ru) 2004-06-24
HK1050853A1 (en) 2003-07-11
ID28035A (id) 2001-05-03
JP5529360B2 (ja) 2014-06-25
CZ2001895A3 (cs) 2001-08-15
HUP0103557A3 (en) 2002-12-28
PL348749A1 (en) 2002-06-03
CN1383382A (zh) 2002-12-04
HU229186B1 (en) 2013-09-30
AU5742199A (en) 2000-04-03

Similar Documents

Publication Publication Date Title
MXPA02010801A (es) Agentes diagnosticos, de representacion y terapeuticos cationicos asociados con sitios vasculares activados.
EA200100111A1 (ru) Ингибиторы фарнезилпротеинтрансферазы, обладающие in vivo радиосенсибилизирующими свойствами
DE602005026789D1 (de) Le
UY26815A1 (es) Métodos para tratar enfermedades reumáticas al usar una molécula ctla4 soluble
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
GT200400242A (es) Uso extendido de combinacion que comprende estrogenos y progestina.
IT1309583B1 (it) Catetere perfezionato per interventi vascolari.
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
DK1472541T3 (da) Afbildningsmidler og metoder til at afbilde NAALADase og PSMA
CL2007002953A1 (es) Compuestos derivados de espiro-oxindol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del dolor, cancer, prurito, hiperplasia prostatica benigna, hipercolesterolemia.
DK1189634T3 (da) Behandling af prostatacancer med anti-ErbB2-antistoffer
WO2005084296A3 (en) Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogernase 3
WO2002046477A3 (en) Endogenous retroviruses up-regulated in prostate cancer
AR027355A1 (es) Acidos tiazolidincarboxilicos
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
CY1110329T1 (el) Πεγκυλιωμενη λιποσωμιακη δοξορουβικινη σε συνδυασμο με εκτεϊνασκιδινη 743
DK1499730T3 (da) Immunokonjugater til behandling af tumorer
MY137766A (en) Exemestane as chemopreventing agent
DK0942754T3 (da) Konjugater anvendelige til behandlingen af prostatacancer
DK0847755T3 (da) Anvendelse af en ekstrakt af cimicifuga racemosa
RS51138B (sr) S-mirtazapin za lečenje nastupa vreline (valunga)
DK1112066T3 (da) Anvendelse af methoxymorpholino doxorubicin til behandlingen af en levertumor
ATE326968T1 (de) Pharmazeutische zusammensetzung enthaltend tenatoprazol und einen entzündungshemmer
NO20015338D0 (no) Androgenderivater og anvendelse derav
BR0014192A (pt) Conjugados de corantes e anticorpos contra estruturas-alvo da angiogênese, para representação intra-operativa da margem de tumores